ASX Listed
& Pre-IPO
Tuesday, 31 May 2022. 5.30 PM AEDT | LIMITED SPOTS AVAILABLE
Keynote Speaker
5.30 PM
Monic Kotecha, Chief Investment Officer at Insync Funds Management
Insync’s Chief Investment Officer, Monik Kotecha, has over 29 years of funds management experience in international and Australian equity markets and has worked in London, New York and Sydney. This included over 7 years as a Senior Portfolio Manager at Investors Mutual Limited, 5 years with BT Funds Management Limited and 3 years with the Abu Dhabi Investment Authority.
Monik was a Senior Portfolio Manager of the Australian Share Fund at Investors Mutual Limited and a key member of the Investment Team which was awarded Fund Manager of the Year Australian Equities in 2002 and 2003 by Money Management. Prior to this Monik was the lead portfolio manager for over 5 years at BT Funds Management Limited on a number of international equity funds and was a member of the asset allocation team. Monik spent the first few years in funds management as a Pan European Equity analyst at the Abu Dhabi Investment Authority in London.
Live Presenting Companies
5.45 PM
Chimeric Therapeutics Ltd (ASX:CHM)
CHM is the ASX leader in cell therapy with a Phase 1 CAR T platform technology in clinical trials for brain cancer developed at the prestigious City Of Hope Cancer Centre in Los Angeles.
Radiopharm Theranostics (ASX:RAD)
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need.
Genex Power Limited (ASX: GNX)
Genex Power Limited (GNX) is an Australian company listed on the ASX, focused on generation and storage of renewable energy.
White Rock Minerals (ASX:WRM)
White Rock Minerals Ltd is an Australian minerals exploration and development company with activities focussed on two projects: Red Mountain and Mt Carrington.
Aegros
Aegros is a pre-IPO biotech company that has built a government-approved blood fractionator, producing therapeutic plasma products for Australia and overseas. Aegros is disrupting the $26.5B plasma fractionation market with its safe, sustainable, and cost-effective technology.
Live Q&A and Networking
6:40 PM
Finally, we have our curated list of ASX listed investors, including yourself, networking post-event to ensure constructive connections are made and thought-provoking ideas are exchanged.